We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Transition Therapeutics has begun patient enrollment for a Phase II clinical
trial of its Interferon Enhancing Therapy (MS-I.E.T.) in patients with multiple
sclerosis (MS).
Angiogenix has announced results from the recently completed Phase II clinical
trial for Acclaim, its product candidate for the prevention of nitrate tolerance
in chronic stable angina patients.
Eli Lilly and Boehringer Ingelheim Pharmaceuticals have jointly announced
that Lilly has withdrawn from the FDA's Division of Reproductive and Urologic
Drug Products its new drug application for duloxetine hydrochloride for the
treatment of stress urinary incontinence (SUI).
Neurobiological Technologies has been granted fast-track status by the FDA
for the investigational drug, Viprinex for its intended use in patients suffering
from ischemic stroke.
YM BioSciences has partnered with the Shin Poong Pharmaceutical of Seoul,
South Korea, to expand the development program for its lead drug, tesmilifene,
into gastric cancer.
Shire Pharmaceuticals Group and New River Pharmaceuticals have signed an agreement
for the global commercialization of NRP104, New River's Phase III compound
for treatment of attention-deficit/hyperactivity disorder (ADHD), as well
as for other potential indications.
Palatin Technologies has released data from preclinical studies that indicate
the company's small molecule, melanocortin receptor subtype-4 (MC4) selective
agonist reduces food intake and body weight and improves metabolic parameters
in rodent models of obesity.